Commentary

Podcast

Eskander Emphasizes the Importance of Inclusivity and Accessibility in Oncology Clinical Trials

Author(s):

Dr Eskander discusses the impact of social determinants of health on cancer clinical trial participation; effective strategies for considering and engaging diverse communities in the clinical trial process; and how community partnerships can be strengthened to eliminate these financial and logistical barriers.

Welcome to OncLive On Air®! I’m your host today, Courtney Flaherty.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by RWJ Barnabas Health and Rutgers Cancer Institute of New Jersey, we had the pleasure of speaking with Mariam F. Eskander, MD, MPH, about efforts to ameliorate disparities in oncology clinical trials. Dr Eskander is a surgical oncologist at the Rutgers Cancer Institute of New Jersey, as well as an assistant professor in the Department of Surgery, Division of Surgical Oncology, and section of Gastrointestinal Oncology at Rutgers Robert Wood Johnson Medical School in New Brunswick.

During the 2023 Rutgers Cancer Institute of New Jersey Annual Oncology Clinical Practice and Research Summit, Eskander delivered a presentation about disparities that exist in clinical trials and ways to eliminate barriers in cancer research.

In our exclusive interview, Dr Eskander discussed the impact of social determinants of health on cancer clinical trial participation; effective strategies for considering and engaging diverse communities in the clinical trial process; and how community partnerships can be strengthened to foster trust, enhance awareness, and eliminate these financial and logistical barriers.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air, sponsored by RWJ Barnabas Health and Rutgers Cancer Institute of New Jersey. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
Malcolm Mattes, MD, associate professor, Section of Radiation Oncology, Rutgers Robert Wood Johnson Medical School; radiation oncologist, Rutgers Cancer Institute of New Jersey
Matthew Matasar, MD, chief, Division of Blood Disorders, Rutgers Cancer Institute; professor, medicine, Rutgers Robert Wood Johnson Medical School
M. Michele Blackwood, MD, FACS, discusses the significance of early cancer screenings.
A panel of 6 experts on chronic lymphocytic leukemia seated at a long desk
A panel of 6 experts on chronic lymphocytic leukemia seated at a long desk
A panel of 6 experts on chronic lymphocytic leukemia seated at a long desk
A panel of 6 experts on chronic lymphocytic leukemia seated at a long desk
A panel of 6 experts on chronic lymphocytic leukemia seated at a long desk
A panel of 6 experts on chronic lymphocytic leukemia seated at a long desk
A panel of 6 experts on chronic lymphocytic leukemia